Moss, 7 January 2026
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of high-quality diagnostic assays, announces that it has entered into an exclusive cooperation agreement with a leading global diagnostics company for the development of a novel assay to be integrated on one of the most widely used clinical chemistry analyser platforms in the world.
Under the agreement, Gentian is responsible for assay development and will also undertake manufacturing upon commercialisation.
In line with the partner’s strategic communications policy, the identity of the biomarker and its specific diagnostic application remain undisclosed. The project is well advanced in the development phase, with current activities focused on optimisation of assay performance and system integration, as well as preparations for subsequent validation activities. Subject to successful completion of development, and regulatory processes, a commercial launch is currently targeted for the second half of 2027.
Upon launch, the assay will be distributed through the partner’s global sales and distribution network, providing Gentian with broad international market access and reinforcing its commitment to scalable, high-quality diagnostic solutions.
This project builds on Gentian’s growing portfolio of successfully commercialized biomarker assays and further solidifies its reputation as a trusted development and manufacturing partner for global diagnostic leaders.
“We are pleased to see this project advancing into the later stages of development in close collaboration with a global diagnostics leader,” says Matti Heinonen, CEO of Gentian Diagnostics. “The agreement reflects confidence in our assay development capabilities and supports our strategy of creating long-term value through strategic partnerships in the global diagnostics market.”
For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.